symptomsrecoveredwithinfewdays.Thetransbronchialbiopsies inthepatientsdescribedbyLerchetal. [1] andThornburgetal. [2] revealedanonspecific,hypersensitivitypneumonitis(compatiblewithtoxicdrug-induceddamage).Immunosuppressivetherapy with steroids induced a rapid relief of all symptoms in all 3cases.Infectiouscauseofthepulmonaryinfiltratescouldbeexcludedbybroncho-alveolarlavage.Noeosinophiliawasfound,as reported in literature in several cases of thalidomide induced pulmonaryreactions.Takingthewell-toleratedthalidomidepretreatmentoftheheredescribedpatientinconsideration,rathera drug-,thanaclass-specificadverseeffectmaybesuggested.Accordingly,Pretzetal.in2009 [3] describeda76-year-oldfemale myeloma patient who had developed a thalidomide induced pneumonitisandshowedagoodtolerancetoasubsequentlenalidomidetherapy.
As described for bortezomib and thalidomide, lenalidomide therapy may cause severe pulmonary side effects in rare cases. The pathomechanism remains unclear, a toxic or immunologicallymediatedmechanismcanbeenvisaged.Physiciansprescribinglenalidomideshouldbeawareofthisrarebutseverepulmonary complication, and should consider a lenalidomide induced hypersensitivitypneumonitisifpatientsdevelopapulmonaryaffection during lenalidomide therapy. Especially in patients not respondingtoantibiotictherapyabroncho-alveolarlavageandif possibleatransbronchialbiopsyarerecommendedtodocumenta hypersensitivityreactionwhichshouldbetreatedbysteroidsand toexcludeaninfectiousdisease.Inthesepatientsfurtherexposition to lenalidomide may be harmful, potential alternatives shouldbeconsidered. Theintroductionoftheso-callednovelagents-bortezomib,thalidomideandlenalidomide-hassignificantlyimprovedtheoutcome of multiple myeloma treatment. Pneumonitis-like side effects occurring during treatment with novel agents are rare but have been described following application of the first-in-class proteasomeinhibitorbortezomibaswellasfortheimmunomodulatorthalidomide,buthadnotyetbeen describedforitssuccessorlenalidomide.
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[1]developing pneumonitis-likesymptomsafter2weeksoftreatmentwithlena-lidomidemonotherapyisthesecondcasereportoflenalidomide induced pulmonary hypersensitivity reaction in literature -assuminglenalidomideasthecausativeagent.Interestingly,thedescribedpatienthadpreviouslyreceivedthelenalidomidepredecessor thalidomide with dexamethasone without showing any pulmonary side effects. The first case report was described in 2007byThornburgetal. [2] wherea60-year-oldfemalemyeloma patientdevelopedsignsofahypersensitivitypneumonitis-likereactionafterreceivinglenalidomideanddexamethasonetherapy. Thesymptomsoccurredaftershehadalreadyreceived2cyclesof therapy;symptomswerepotentiallydelayedbytheintense,concomitant high-dose steroid treatment. In contrast a 58-year-old, malemyelomapatientinourcenter,receivingjustashortcourse ofsteroidtreatmentinalenalidomide,adriamycin,anddexamethasonetherapyin2008,showedasuddenonset,developingpulmonary infiltrates and requiring hospitalization. This happened shortly after he had finished dexamethasone therapy and after hadbeenonlenalidomidetherapyforonlyafewdays.Lenalidomide therapy was stopped and antibiotic treatment was started whichledtoaslowrecovery.Afterhehadfullyrecoveredfrom thepulmonarysymptomsthesecondcourseoflenalidomidetherapywasstarted,leadingagaintosuddenpneumonitis-likesymptoms.Thistimebroncho-alveolarlavagewasperformedwithout anydocumentationofbacterial,viralorfungalinfection,alenalidomide induced pulmonary drug reaction was assumed. After treatment with steroids and intravenous antibiotics, pulmonary
